EC grants marketing authorisation for Actelion ’s Ledaga to treat MF-CTCL

The European Commission (EC) has granted marketing authorisation for 160mcg of Actelion ’s Ledaga (chlormethine gel) to treat mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news